MAKE WAY FOR THE FIRST ACTIVE HEMOSTATIC POWDER

MAKE WAY FOR THE FIRST ACTIVE HEMOSTATIC POWDER

NEWS UND VERANSTALTUNGEN

07 MÄRZ 2018

NAMSA – Biom’up Achieves Record-Breaking Medical Device Development Timelines with NAMSA’s MRO® Approach Interview of Etienne Binant, Biomu’up CEO and Rachid Zerouali, Sales director EMEA at Namsa Watch the full video: https://www.youtube.com/watch?v=M4rbvoJ90_U  

Lesen Sie mehr

6 MÄRZ 2018

Biom’up is proud to receive the Lyon Metropolis president (David Kimelfeld) in our headquarters in St-Priest.  

Lesen Sie mehr

14 FEBRUAR 2018

Euronext – Biom’up Announces a Financing Targeting a Total of €43m Capital increase of an initial amount of €18m which may be increased to €20.7m by means of a public offering without preferential subscription rights and with a priority subscription period of three trading days as of right only Proposed bond…

Lesen Sie mehr

18 DECEMBER 2017

Biom’up receives FDA marketing approval  for HEMOBLAST™ Bellows, its flagship product -Approval granted several months ahead of the initial schedule -Launch of HEMOBLAST™ Bellows in the United States expected over the summer in 2018 Read more:

Lesen Sie mehr

13 DECEMBER 2017

Biom’up to be included in the Euronext’s CAC® Small, CAC® Mid & Small and CAC® All-Tradable indexes  Saint-Priest, France, December 13, 2017 – Biom’Up, specialist in surgical hemostasis, announces today that, as of Monday December 18, 2017, it will be included in three new CAC-family indexes: CAC® Small, CAC® Mid…

Lesen Sie mehr

07 DECEMBER 2017

Biom’up appoints Cécile Ferracci as Global Vice President Marketing  Etienne Binant, Chief Executive Officer of Biom’Up, says: “I am delighted to welcome Cécile Ferracci to Biom’up as our Global Vice-President, Marketing. Her solid and diverse experience within global medical technology companies represents a crucial asset for Biom’up’s success at a…

Lesen Sie mehr

09 NOVEMBER 2017

Biom’up confirms the success of its IPO Reinforcement of shareholders‘ equity of €60 million through the initial public offering of witch: – around €42.5 million within the frame of the offer – €17.3 million in bonds capitalization Implementation of a liquidity contract with CM-CIC Market Solutions Read more:

Lesen Sie mehr

27 OCTOBER 2017

Biom’up provides regulatory update regarding HEMOBLAST™ Bellows  Saint-Priest, France, October 27, 2017 – Biom’Up, specialist of surgical hemostasis, today provides a regulatory update regarding the United States Food and Drug Administration’s (FDA) review of the company’s Premarket Approval (PMA) application for its HEMOBLASTTM Bellows. The FDA conducted a PMA pre-approval…

Lesen Sie mehr

11 OCTOBER 2017

Biom’up announces the success of its IPO,  raising close to €38.1 million on Euronext Paris  -First initial public offering in the healthcare sector on the Euronext regulated market in Paris in the last 6 months -Strong institutional demand in France as well as abroad, especially in the United States and…

Lesen Sie mehr

VOM 10. BIS 12. OKTOBER 2017 – EURO-PHARMAT

Wir freuen uns, Ihnen bekanntgeben zu können, dass wir vom 10. bis zum 12. Oktober am Euro-Pharmat-Kongress in Saint Malo teilnehmen werden. Stand Nr. 92 EURO-PHARMAT / Palais des Congrès le Grand Large / Saint Malo

Lesen Sie mehr

Rechtliche Informationen: HEMOBLAST™ Bellows - Implantierbares Medizinprodukt der Klasse III für die Chirurgie, nur für den Gebrauch durch qualifizierte medizinische Fachkräfte vorgesehen, Erstattung abhängig vom jeweiligen Land.
Vor Gebrauch die Anweisungen auf der Verpackung sorgfältig durchlesen. CE0086: BSI - Hersteller: Biom’up SA Frankreich.